Insider Trading Alert - SPLK, ARE And THRX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 13, 2014, 117 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,198.88 to $4,397,881,850,959.55.

Highlighted Stocks Traded by Insiders:

Splunk (SPLK) - FREE Research Report

Neustaetter Thomas M who is Director at Splunk sold 1,500 shares at $82.79 on Feb. 13, 2014. Following this transaction, the Director owned 67,103 shares meaning that the stake was reduced by 2.19% with the 1,500-share transaction.

The shares most recently traded at $85.29, up $2.50, or 2.93% since the insider transaction. Historical insider transactions for Splunk go as follows:

  • 4-Week # shares sold: 45,500
  • 12-Week # shares sold: 101,635
  • 24-Week # shares sold: 361,748

The average volume for Splunk has been 1.5 million shares per day over the past 30 days. Splunk has a market cap of $9.4 billion and is part of the technology sector and computer software & services industry. Shares are up 20.93% year-to-date as of the close of trading on Thursday.

Splunk, Inc. provides software solutions that provide real-time operational intelligence. Currently there are 12 analysts that rate Splunk a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPLK - FREE

TheStreet Quant Ratings rates Splunk as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Splunk Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alexandria Real Estate Equities (ARE) - FREE Research Report

Richardson James H who is Director at Alexandria Real Estate Equities sold 2,500 shares at $71.78 on Feb. 13, 2014. Following this transaction, the Director owned 112,500 shares meaning that the stake was reduced by 2.17% with the 2,500-share transaction.

Historical insider transactions for Alexandria Real Estate Equities go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares sold: 17,000
  • 24-Week # shares sold: 34,000

The average volume for Alexandria Real Estate Equities has been 492,000 shares per day over the past 30 days. Alexandria Real Estate Equities has a market cap of $5.1 billion and is part of the financial sector and real estate industry. Shares are up 12.61% year-to-date as of the close of trading on Thursday.

Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry. The stock currently has a dividend yield of 3.82%. The company has a P/E ratio of 44.8. Currently there are 4 analysts that rate Alexandria Real Estate Equities a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARE - FREE

TheStreet Quant Ratings rates Alexandria Real Estate Equities as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Alexandria Real Estate Equities Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Theravance (THRX) - FREE Research Report

Glaxosmithkline Plc who is 10% Owner at Theravance bought 342,229 shares at $12,850,698.95 on Feb. 13, 2014. Following this transaction, the 10% Owner owned 30.3 million shares meaning that the stake was reduced by 1.14% with the 342,229-share transaction.

The shares most recently traded at $39.61, down $12,850,659.34, or 32442967.28% since the insider transaction. Historical insider transactions for Theravance go as follows:

  • 12-Week # shares sold: 22,353
  • 24-Week # shares sold: 22,353

The average volume for Theravance has been 946,700 shares per day over the past 30 days. Theravance has a market cap of $4.2 billion and is part of the health care sector and drugs industry. Shares are up 7.91% year-to-date as of the close of trading on Thursday.

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. Currently there are 5 analysts that rate Theravance a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on THRX - FREE

TheStreet Quant Ratings rates Theravance as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Theravance Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk